MVCD5
MCID: MCR115
MIFTS: 57

Microvascular Complications of Diabetes 5 (MVCD5) malady

Categories: Genetic diseases, Eye diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 5

Aliases & Descriptions for Microvascular Complications of Diabetes 5:

Name: Microvascular Complications of Diabetes 5 54 66 29 13 38
Diabetic Retinopathy 38 12 29 52 42 14 69
Diabetic Nephropathy 66 69
Retinal Abnormality - Diabetes-Related 12
Mvcd5 66

Classifications:



External Ids:

OMIM 54 612633
Disease Ontology 12 DOID:8947
ICD9CM 35 362.0
NCIt 47 C34538
MedGen 40 C2674665
ICD10 33 H36.0
UMLS 69 C0011884

Summaries for Microvascular Complications of Diabetes 5

UniProtKB/Swiss-Prot : 66 Microvascular complications of diabetes 5: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 5, also known as diabetic retinopathy, is related to background diabetic retinopathy and severe nonproliferative diabetic retinopathy. An important gene associated with Microvascular Complications of Diabetes 5 is PON1 (Paraoxonase 1), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acarbose and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include Eye and Eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

Description from OMIM: 612633

Related Diseases for Microvascular Complications of Diabetes 5

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 7
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 5 Microvascular Complications of Diabetes 3

Diseases related to Microvascular Complications of Diabetes 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
id Related Disease Score Top Affiliating Genes
1 background diabetic retinopathy 12.1
2 severe nonproliferative diabetic retinopathy 12.1
3 microvascular complications of diabetes 3 11.6
4 microvascular complications of diabetes 4 11.5
5 microvascular complications of diabetes 7 11.5
6 microvascular complications of diabetes 1 11.5
7 microvascular complications of diabetes 6 11.5
8 microvascular complications of diabetes 2 11.5
9 diabetic angiopathy 10.8
10 endotheliitis 10.3
11 congenital toxoplasmosis 10.3 AKR1B1 SERPINF1 VEGFA
12 spondyloarthropathy 2 10.3 ACE ALB VEGFA
13 benign familial neonatal epilepsy 10.3 KDR SERPINF1 VEGFA
14 kidney osteogenic sarcoma 10.3 FLT1 KDR VEGFA
15 ependymoblastoma 10.3 ALB ICAM1 VCAM1
16 adult infiltrating astrocytic neoplasm 10.3 ANGPT2 SERPINF1 VEGFA
17 neuropathy with hearing impairment 10.3 FLT1 KDR VEGFA
18 ovarian disease 10.2 FLT1 KDR VEGFA
19 spinocerebellar ataxia 25 10.2 ALB KDR VEGFA
20 exophthalmic ophthalmoplegia 10.2 ALB VCAM1 VEGFA
21 brucella canis brucellosis 10.2 IGF1 INS VEGFA
22 fissured tongue 10.2 AKR1B1 ALB INS
23 limbal stem cell deficiency 10.2 AKR1B1 IGF1 VCAM1
24 dilated cardiomyopathy 10.2 ACE AKR1B1 INS VEGFA
25 localized junctional epidermolysis bullosa, non-herlitz type 10.2 ANGPT2 FLT1 VEGFA
26 zellweger syndrome 10.2 ALB NOS3 VEGFA
27 submucous uterine fibroid 10.2 ALB ANGPT2 INS VEGFA
28 hypersensitivity syndrome, carbamazepine-induced 10.2 ALB ANGPT2 INS VEGFA
29 capillary hemangioma 10.2 ALB NOS3 VEGFA
30 benign idiopathic neonatal seizures 10.2 FGF2 KDR VEGFA
31 multilocular clear cell renal cell carcinoma 10.2 ICAM1 PRKCB SERPINF1 VEGFA
32 bipolar i disorder 10.2 ANGPT2 FGF2 VEGFA
33 chronic myocardial ischemia 10.2 ACE ALB INS VCAM1
34 neurilemmoma of the pleura 10.2 FGF2 KDR VEGFA
35 chronic tic disorder 10.2 ALB FLT1 VCAM1 VEGFA
36 phlegmonous dacryocystitis 10.2 ICAM1 KDR VCAM1 VEGFA
37 vesiculobullous skin disease 10.2 KDR TEK VEGFA
38 papillary craniopharyngioma 10.2 IGF1 INS VEGFA
39 scar contracture 10.2 SERPINE1 SERPINF1 VEGFA
40 periosteal chondrosarcoma 10.2 ICAM1 SERPINE1 VCAM1
41 intra-abdominal lymph node mast cell malignancy 10.2 ACE ICAM1 VCAM1
42 radiation induced angiosarcoma of the breast 10.2 ANGPT2 TEK VEGFA
43 metagonimiasis 10.2 FGF2 KDR VEGFA
44 perrault syndrome 10.2 ICAM1 SERPINE1 VCAM1
45 prostate neuroendocrine neoplasm 10.2 ACE AGTR1 ALB
46 focal dystonia 10.2 ACE NOS3 VCAM1 VEGFA
47 craniopharyngioma 10.2 ICAM1 SERPINE1 VCAM1
48 xerophthalmia 10.2 ICAM1 SERPINE1 VCAM1
49 contagious pustular dermatitis 10.2 ACE PON1 VEGFA
50 cleft palate cardiac defect ectrodactyly 10.2 KDR SERPINE1 VEGFA

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 5:



Diseases related to Microvascular Complications of Diabetes 5

Symptoms & Phenotypes for Microvascular Complications of Diabetes 5

Clinical features from OMIM:

612633

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 5:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.48 PRKCB SERPINE1 SERPINF1 TEK VCAM1 VEGFA
2 homeostasis/metabolism MP:0005376 10.47 ACE AGTR1 AKR1B1 ALB ANGPT2 FGF2
3 hematopoietic system MP:0005397 10.39 ICAM1 IGF1 INS KDR NOS3 PRKCB
4 growth/size/body region MP:0005378 10.34 ACE AGTR1 AKR1B1 FLT1 ICAM1 IGF1
5 mortality/aging MP:0010768 10.34 ACE AGTR1 AKR1B1 ALB ANGPT2 FGF2
6 immune system MP:0005387 10.32 INS KDR NOS3 PRKCB SERPINE1 SERPINF1
7 cellular MP:0005384 10.31 ALB ANGPT2 FGF2 FLT1 ICAM1 IGF1
8 muscle MP:0005369 10.1 INS KDR NOS3 TEK VEGFA ALB
9 nervous system MP:0003631 10.1 FGF2 FLT1 ICAM1 IGF1 INS KDR
10 liver/biliary system MP:0005370 10 ACE ALB INS KDR NOS3 SERPINE1
11 neoplasm MP:0002006 9.91 VEGFA ACE ALB FGF2 ICAM1 IGF1
12 normal MP:0002873 9.91 ALB FLT1 IGF1 INS KDR NOS3
13 renal/urinary system MP:0005367 9.81 ACE AGTR1 AKR1B1 ALB IGF1 INS
14 reproductive system MP:0005389 9.61 IGF1 INS NOS3 SERPINF1 VCAM1 VEGFA
15 vision/eye MP:0005391 9.4 AKR1B1 ANGPT2 FGF2 FLT1 ICAM1 INS

Drugs & Therapeutics for Microvascular Complications of Diabetes 5

Drugs for Microvascular Complications of Diabetes 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 426)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
4
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
5
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
6
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
7
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
8
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
9
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129497-78-5
10
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
11
Nitric Oxide Approved Phase 4 10102-43-9 145068
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
13
Insulin Glargine Approved Phase 4,Early Phase 1 160337-95-1
14
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
15
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
16
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 124-94-7 31307
17
Temazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-50-4 5391
18
Copper Approved Phase 4,Phase 2,Phase 1 15158-11-9, 7440-50-8 27099
19
Nepafenac Approved Phase 4,Phase 3,Phase 2 78281-72-8 151075
20
Insulin Lispro Approved Phase 4 133107-64-9
21
Metformin Approved Phase 4,Phase 3,Early Phase 1 657-24-9 14219 4091
22
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
23
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
24
Dipivefrin Approved Phase 4 52365-63-6 3105
25
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
26
Menthol Approved Phase 4 2216-51-5 16666
27
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 378-44-9 9782
28
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
29
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
30
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 150310 443872
31
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
32
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 67-73-2 6215
33
Ketorolac Approved Phase 4,Phase 2,Phase 1 74103-06-3, 66635-83-4 3826
34
Amlodipine Approved Phase 4 88150-42-9 2162
35
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
36
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
37
Enalapril Approved, Vet_approved Phase 4,Phase 2 75847-73-3 5362032 40466924
38
Enalaprilat Approved Phase 4,Phase 2 76420-72-9 6917719
39
Lisinopril Approved, Investigational Phase 4 83915-83-7 5362119
40
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
41
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
42
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
43
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
44
Empagliflozin Approved Phase 4 864070-44-0
45
Glimepiride Approved Phase 4 93479-97-1 3476
46
Bisoprolol Approved Phase 4 66722-44-9 2405
47
Captopril Approved Phase 4 62571-86-2 44093
48
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
49
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56329 56330
50
Eprosartan Approved Phase 4 133040-01-4 5281037

Interventional clinical trials:

(show top 50) (show all 948)
id Name Status NCT ID Phase
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4
2 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
3 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
4 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4
5 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4
6 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4
7 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4
8 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4
9 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4
10 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4
11 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
12 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
13 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
14 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4
15 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4
16 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
17 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
18 The Endurance 1 Trial Unknown status NCT02297204 Phase 4
19 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4
20 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4
21 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
22 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4
23 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4
24 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4
25 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
26 Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients Completed NCT00174824 Phase 4
27 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4
28 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4
29 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4
30 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4
31 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4
32 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4
33 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
34 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4
35 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
36 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4
37 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4
38 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4
39 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4
40 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4
41 20- Versus 23- Gauge System for Pars Plana Vitrectomy Completed NCT00411970 Phase 4
42 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4
43 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4
44 Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Completed NCT01310127 Phase 4
45 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4
46 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4
47 A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis Completed NCT00682643 Phase 4
48 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4
49 CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Completed NCT00327418 Phase 4
50 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4

Search NIH Clinical Center for Microvascular Complications of Diabetes 5

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetic retinopathy

Genetic Tests for Microvascular Complications of Diabetes 5

Genetic tests related to Microvascular Complications of Diabetes 5:

id Genetic test Affiliating Genes
1 Diabetic Retinopathy 29
2 Microvascular Complications of Diabetes 5 29

Anatomical Context for Microvascular Complications of Diabetes 5

MalaCards organs/tissues related to Microvascular Complications of Diabetes 5:

39
Bone, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 5:
id Tissue Anatomical CompartmentCell Relevance
1 Eye Outer Nuclear Layer Mature L Cone Cells Potential therapeutic candidate, affected by disease
2 Eye Outer Nuclear Layer Mature M Cone Cells Potential therapeutic candidate, affected by disease
3 Eye Inner Nuclear Layer Mature Muller Glia Cells Affected by disease
4 Eye Outer Nuclear Layer Mature Rod Cells Potential therapeutic candidate, affected by disease
5 Eye Outer Nuclear Layer Mature S Cone Cells Potential therapeutic candidate, affected by disease

Publications for Microvascular Complications of Diabetes 5

Variations for Microvascular Complications of Diabetes 5

ClinVar genetic disease variations for Microvascular Complications of Diabetes 5:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PON1 NM_000446.5(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 GRCh37 Chromosome 7, 94946084: 94946084

Expression for Microvascular Complications of Diabetes 5

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 5.

Pathways for Microvascular Complications of Diabetes 5

Pathways related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 ANGPT2 FLT1 INS KDR NOS3 PRKCB
2
Show member pathways
13.51 AGTR1 ANGPT2 FGF2 FLT1 ICAM1 IGF1
3
Show member pathways
13.43 ANGPT2 FGF2 FLT1 IGF1 KDR NOS3
4
Show member pathways
13.33 ALB ANGPT2 IGF1 NOS3 PRKCB SERPINE1
5
Show member pathways
13.31 ANGPT2 FGF2 FLT1 IGF1 KDR PRKCB
6
Show member pathways
13.29 FGF2 FLT1 IGF1 KDR NOS3 PRKCB
7
Show member pathways
13.03 FGF2 FLT1 IGF1 INS KDR PRKCB
8
Show member pathways
12.97 ACE AGTR1 FGF2 FLT1 IGF1 INS
9
Show member pathways
12.8 IGF1 KDR NOS3 PRKCB VEGFA
10
Show member pathways
12.75 FGF2 ICAM1 KDR SERPINE1 VCAM1
11
Show member pathways
12.71 FGF2 FLT1 IGF1 KDR PRKCB
12 12.68 AGTR1 FGF2 IGF1 PRKCB VEGFA
13
Show member pathways
12.66 ICAM1 KDR NOS3 PRKCB VCAM1 VEGFA
14
Show member pathways
12.66 ANGPT2 FGF2 FLT1 IGF1 INS KDR
15
Show member pathways
12.61 AGTR1 ANGPT2 FGF2 NOS3 TEK
16
Show member pathways
12.52 FLT1 IGF1 INS KDR PRKCB
17 12.44 ANGPT2 FGF2 FLT1 IGF1 INS KDR
18
Show member pathways
12.41 AGTR1 ALB INS PRKCB
19
Show member pathways
12.39 FGF2 FLT1 KDR VEGFA
20
Show member pathways
12.36 ICAM1 KDR NOS3 PRKCB VCAM1 VEGFA
21
Show member pathways
12.34 FLT1 KDR NOS3 PRKCB VEGFA
22
Show member pathways
12.33 ALB ICAM1 INS SERPINE1
23 12.29 FGF2 IGF1 KDR PRKCB VEGFA
24
Show member pathways
12.19 FGF2 FLT1 KDR NOS3 PRKCB VEGFA
25 12.09 ANGPT2 FGF2 FLT1 KDR TEK
26 12.06 ICAM1 KDR NOS3 VCAM1 VEGFA
27 12 FGF2 ICAM1 VCAM1 VEGFA
28 11.99 ALB FGF2 IGF1 INS KDR VCAM1
29 11.9 FGF2 IGF1 INS VCAM1
30
Show member pathways
11.88 FLT1 KDR NOS3 VEGFA
31 11.86 FLT1 ICAM1 TEK VEGFA
32
Show member pathways
11.82 FLT1 KDR NOS3 PRKCB
33 11.82 ANGPT2 FGF2 FLT1 KDR NOS3 TEK
34
Show member pathways
11.79 ACE AGTR1 NOS3
35 11.79 FGF2 IGF1 VEGFA
36 11.7 AGTR1 ICAM1 NOS3 PRKCB SERPINE1 VCAM1
37 11.69 INS NOS3 PRKCB
38 11.68 FGF2 IGF1 VEGFA
39
Show member pathways
11.67 ICAM1 VCAM1 VEGFA
40 11.57 FGF2 IGF1 INS KDR
41 11.55 FGF2 KDR VEGFA
42 11.51 FGF2 KDR VEGFA
43 11.5 ICAM1 NOS3 VCAM1
44 11.49 FGF2 IGF1 INS VEGFA
45
Show member pathways
11.47 INS KDR VEGFA
46 11.41 IGF1 INS PRKCB
47 11.4 ANGPT2 SERPINE1 VEGFA
48 11.37 ICAM1 PRKCB VCAM1
49 11.31 FLT1 KDR SERPINE1 VEGFA
50 11.27 ANGPT2 FLT1 IGF1 INS NOS3 PRKCB

GO Terms for Microvascular Complications of Diabetes 5

Cellular components related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 ACE AKR1B1 ALB ICAM1 PON1 PRKCB
2 extracellular region GO:0005576 9.77 ACE ALB ANGPT2 FGF2 FLT1 IGF1
3 extracellular space GO:0005615 9.5 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
4 platelet alpha granule lumen GO:0031093 9.46 ALB IGF1 SERPINE1 VEGFA

Biological processes related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 FGF2 ICAM1 KDR TEK
2 peptidyl-tyrosine phosphorylation GO:0018108 9.95 FGF2 FLT1 KDR TEK
3 platelet degranulation GO:0002576 9.91 ALB IGF1 SERPINE1 VEGFA
4 extracellular matrix organization GO:0030198 9.89 FGF2 ICAM1 KDR SERPINE1 VCAM1
5 kidney development GO:0001822 9.86 ACE AGTR1 SERPINF1 VEGFA
6 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 FLT1 KDR VEGFA
7 positive regulation of cell migration GO:0030335 9.85 FLT1 IGF1 INS KDR VEGFA
8 negative regulation of angiogenesis GO:0016525 9.84 ANGPT2 SERPINF1 TEK
9 positive regulation of MAP kinase activity GO:0043406 9.83 FGF2 FLT1 VEGFA
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 ICAM1 IGF1 INS VEGFA
11 positive regulation of MAPK cascade GO:0043410 9.81 FLT1 IGF1 INS KDR
12 response to hypoxia GO:0001666 9.8 ANGPT2 ICAM1 PRKCB TEK VCAM1 VEGFA
13 positive regulation of endothelial cell migration GO:0010595 9.79 KDR TEK VEGFA
14 positive regulation of endothelial cell proliferation GO:0001938 9.78 FGF2 KDR TEK VEGFA
15 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.77 ICAM1 NOS3 SERPINE1
16 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.74 FGF2 FLT1 TEK
17 positive regulation of focal adhesion assembly GO:0051894 9.71 KDR TEK VEGFA
18 negative regulation of calcium ion transport GO:0051926 9.68 ICAM1 NOS3
19 negative regulation of wound healing GO:0061045 9.68 FGF2 SERPINE1
20 positive regulation of positive chemotaxis GO:0050927 9.68 KDR VEGFA
21 positive regulation of phospholipase C activity GO:0010863 9.67 FGF2 FLT1
22 regulation of blood vessel diameter GO:0097746 9.67 ACE AGTR1
23 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 ICAM1 KDR SERPINE1 TEK
24 vascular endothelial growth factor signaling pathway GO:0038084 9.65 FLT1 KDR
25 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.64 ACE AGTR1
26 receptor-mediated virion attachment to host cell GO:0046813 9.64 ACE ICAM1
27 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.63 ACE VEGFA
28 membrane to membrane docking GO:0022614 9.63 ICAM1 VCAM1
29 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 KDR VEGFA
30 glomerulus vasculature development GO:0072012 9.61 ANGPT2 TEK
31 cell migration involved in sprouting angiogenesis GO:0002042 9.61 FGF2 KDR VEGFA
32 Tie signaling pathway GO:0048014 9.58 ANGPT2 TEK
33 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.58 FLT1 PRKCB VEGFA
34 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.56 FLT1 KDR VCAM1 VEGFA
35 angiogenesis GO:0001525 9.56 ANGPT2 FGF2 FLT1 KDR NOS3 SERPINE1
36 fructose biosynthetic process GO:0046370 9.55 AKR1B1 SORD
37 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 FLT1 IGF1 INS KDR TEK
38 positive regulation of angiogenesis GO:0045766 9.28 ANGPT2 FGF2 FLT1 KDR NOS3 PRKCB
39 negative regulation of apoptotic process GO:0043066 10.07 AKR1B1 ALB IGF1 KDR TEK VEGFA
40 positive regulation of cell proliferation GO:0008284 10.05 FGF2 FLT1 IGF1 INS KDR VEGFA

Molecular functions related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.56 FGF2 FLT1 KDR TEK
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 FLT1 KDR TEK
3 vascular endothelial growth factor-activated receptor activity GO:0005021 9.37 FLT1 KDR
4 growth factor binding GO:0019838 9.33 FLT1 KDR TEK
5 integrin binding GO:0005178 9.26 ICAM1 IGF1 KDR VCAM1
6 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1

Sources for Microvascular Complications of Diabetes 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....